Sun Pharmaceutical Industries Limited reported its consolidated financial results for the third quarter ended December 31, 2025. The results were approved by the Board of Directors at its meeting held today.
For Q3FY26, Sun Pharma recorded revenue from operations of ₹15,520.5 crore, compared with ₹13,675.4 crore in Q3FY25, registering a year-on-year growth of 13.5%.
EBITDA for the quarter stood at ₹4,948.5 crore, up 23.4% YoY from ₹4,009.0 crore in the corresponding quarter last year. The EBITDA margin improved to 31.9% in Q3FY26 from around 29.9% in Q3FY25.
Profit before exceptional items and tax increased to ₹4,716.6 crore, compared with ₹3,792.6 crore in Q3FY25, reflecting a year-on-year rise of 24.4%.
Net profit for the quarter came in at ₹3,368.8 crore, up 16.0% YoY from ₹2,903.4 crore reported in the same quarter of the previous financial year.
During the quarter, Global Innovative Medicines sales were reported at US$ 423 million, including a US$ 55 million milestone payment. Excluding the milestone, Innovative Medicines sales grew 13.2% year-on-year and contributed 21.2% to consolidated sales.
Research and development expenditure for Q3FY26 was ₹892.8 crore, representing 5.8% of quarterly sales.
9MFY26 Financial Performance
For the nine months ended December 31, 2025, Sun Pharma reported consolidated revenue of ₹43,660.4 crore, compared with ₹39,225.7 crore in the same period last year, reflecting a growth of 11.3% year-on-year.
EBITDA for the nine-month period stood at ₹13,777.2 crore, up 19.2% YoY, with an EBITDA margin of 31.4%.
Profit before exceptional items and tax for 9MFY26 increased to ₹12,875.0 crore, compared with ₹10,813.9 crore in 9MFY25, registering a 19.1% year-on-year increase.
Net profit for the nine-month period was ₹8,765.4 crore.
R&D expenditure during 9MFY26 amounted to ₹2,578.3 crore, accounting for 5.9% of sales. Global Innovative Medicines sales for the period stood at US$ 1,067 million, up 15.7% year-on-year, contributing 21.3% of total revenue.
Dividend Announcement
The Board of Directors declared an interim dividend of ₹11.00 per equity share for FY26, compared with an interim dividend of ₹10.50 per share declared in the previous financial year.
